Clinical trials
Gastric or Esophagogastric Junction Adenocarcinoma clinical trials
Below are recruiting gastric or esophagogastric junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 925 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT04997837RecruitingPhase 3
Adjuvant chemo with or without PD-1 for stomach cancer after surgery
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05539105Recruiting
Watching recovery after surgery for upper stomach cancer
This study keeps track of how people recover after surgery to remove the upper part of the stomach and nearby lymph nodes. It mainly helps doctors understand which surgical reconstruction methods work best and how patients do over time.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT02988921Recruiting
MRI and CT planning for esophagus or stomach-junction cancer treatment
This study checks whether MRI and CT scans can better measure how esophageal or stomach-junction tumors respond during chemoradiotherapy and help doctors map the exact treatment area. It may help improve targeting while you receive standard treatment.
BeijingAges 18 years+ - NCT07829081Recruiting
Watch-and-wait after immunotherapy for early-stage GI cancers
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
BaselAges 18 years+ - NCT07692204RecruitingPhase 2
Testing a new drug for advanced stomach cancer
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
ShanghaiAges 18 years+ - NCT06662110Recruiting
Blood test to predict chemo and immunotherapy response in stomach cancer
This trial tests whether a blood test (called immune proteomics) can predict how well chemotherapy and immunotherapy work in people with stomach cancer. If you qualify, you would receive standard chemo or chemo plus immunotherapy before surgery, and researchers will study your blood to see if it can guide future treatment.
Xuhui District, Shanghai MunicipalityAges 18–75 - NCT07670312RecruitingPhase 1/Phase 2
Testing XYA02 for advanced solid tumors
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
Sydney, New South WalesAges 18 years+ - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06760858Recruiting
Study of treatment for advanced stomach cancer
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06786169Recruiting
Stress and treatment results in stomach cancer
This study looks at how psychological stress affects treatment success and long-term outcomes in people with stomach cancer. It includes three different groups of patients at various stages of the disease.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07464756RecruitingPhase 2
Study of SHR-1701 and apatinib with chemo before stomach cancer surgery
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
Nanjing, JiangsuAges 18 years+ - NCT07429487Recruiting
Smartwatch activity tracking for fatigue after chemo
This study uses a smartwatch to track your physical activity and see if it helps reduce tiredness after finishing chemotherapy. It is for people who finished treatment for certain cancers less than 3 months ago.
NiceAges 18–75 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06289374Recruiting
Long-term breath & blood study after stomach or esophagus cancer surgery
This study is for people who have had surgery for stomach or esophagus adenocarcinoma and are already part of a larger study called BIORESOURCE 1. It looks at certain substances in your breath and blood over time to learn more about recovery.
LondonAges 18–90 - NCT05303714RecruitingPhase 3
PIPAC plus chemo for limited peritoneal stomach cancer
This trial tests a treatment called PIPAC (medicine delivered into the abdomen through a small scope) along with “multimodal” therapy, including chemotherapy, for stomach cancer that has spread only in the lining of the abdomen in limited amounts. It may help control the cancer and prevent progression after surgery.
VeronaAges 18–75 - NCT07270991RecruitingPhase 3
Testing a new drug combo for advanced stomach or esophageal cancer
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
AurillacAges 18 years+ - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT07217704RecruitingPhase 3
New PET scan to find stomach or esophageal cancer spread
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
Cerritos, CaliforniaAges 18 years+ - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07176312RecruitingPhase 2
Zanidatamab with pembrolizumab and chemo for HER2+ and PD-L1+ stomach cancer
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
BerlinAges 18 years+ - NCT07178808RecruitingPhase 2
Surgery and heated chemotherapy for stomach cancer
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
Gilbert, ArizonaAges 18 years+ - NCT07165847RecruitingPhase 2
Combination therapy before surgery for gastric cancer
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chongqing, Other (Non U.s.)Ages 18 years+ - NCT07098026Recruiting
Herbal mixture plus chemo before surgery for advanced stomach cancer
This trial tests whether adding an herbal mixture (Shenqi Fuwei Mixture) to standard chemotherapy before surgery can help treat locally advanced stomach cancer. It is for people whose cancer has not spread to distant sites and who are healthy enough to undergo treatment and surgery.
Changsha, HunanAges 18–75
Hear when a new Gastric or Esophagogastric Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric or esophagogastric junction adenocarcinoma?
- Yes. Clin2 currently lists 925 recruiting gastric or esophagogastric junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric or esophagogastric junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric or esophagogastric junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Adenocarcinoma of Esophagogastric Junction
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Gastric Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.